Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

"The monthly installments, if taken for 20 years, are approximately Rp1 million. This already includes fire, credit, and life insurance," said Heru. Minister of Home Affairs Muhammad Tito Karnavian ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

President Prabowo Subianto instructed Health Minister Budi Gunadi Sadikin to increase the number of dentists at public health ...

GoTo had a connection to the procurement process and mechanisms for Google Cloud at Kemendikbudristek during that time.

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

PT Pradiksi Gunatama Tbk (PGUN), a palm oil company owned by Indonesian tycoon Andi Syamsuddin Arsyad (popularly known as ...

The insurer recorded an APE of $122.0m. PT Asuransi BRI Life (BRI Life) topped Indonesia’s life insurance industry in the ...

Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE ...